Lumasiran

An RNA interference therapeutic for primary hyperoxaluria type 1

Lumasiran

Chemical structure of Lumasiran

Lumasiran is a medication used in the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by the overproduction of oxalate, leading to kidney stones and renal failure. Lumasiran is an RNA interference (RNAi) therapeutic that targets the hydroxyacid oxidase 1 (HAO1) gene, which encodes the enzyme glycolate oxidase. By reducing the production of glycolate oxidase, Lumasiran decreases the conversion of glycolate to glyoxylate, thereby reducing the production of oxalate.

Mechanism of Action

Lumasiran works by utilizing the natural cellular process of RNA interference to silence the expression of the HAO1 gene. This gene is responsible for the production of glycolate oxidase, an enzyme that plays a crucial role in the metabolic pathway leading to oxalate production. By inhibiting this enzyme, Lumasiran effectively reduces the levels of oxalate in the body, thereby mitigating the symptoms and complications associated with primary hyperoxaluria type 1.

Administration and Dosage

Lumasiran is administered via subcutaneous injection. The dosing regimen typically involves an initial loading phase followed by maintenance doses. The specific dosage and frequency depend on the patient's body weight and the severity of the condition. It is important for healthcare providers to monitor patients regularly to adjust the dosage as needed and to assess the therapeutic response.

Side Effects

Common side effects of Lumasiran include injection site reactions, such as redness, swelling, and pain. Some patients may also experience gastrointestinal symptoms, such as nausea and abdominal pain. It is important for patients to report any adverse effects to their healthcare provider, as these may require medical attention or adjustment of the treatment regimen.

Clinical Trials

Lumasiran has undergone extensive clinical trials to evaluate its safety and efficacy in patients with primary hyperoxaluria type 1. These trials have demonstrated significant reductions in urinary oxalate levels, which correlate with a decrease in the risk of kidney stone formation and renal damage. The results of these trials have supported the approval of Lumasiran for the treatment of PH1.

Related pages

• Primary hyperoxaluria
• RNA interference
• Kidney stone
• Genetic disorder